Why Vertex picked elexacaftor for CF triple combo regimen

Vertex said it selected elexacaftor (VX-445) as the third component of its cystic fibrosis combination therapy after reporting updated Phase III data on Thursday. The company reiterated its plans to submit an NDA to FDA next quarter and an MAA to EMA

Read the full 422 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE